Current mood:

productive

Fluoxetine: an assessment on evidence based medicine
The paper evaluating efficacy and safety of fluoxetine to the short-term management of major depression[31], calculated the chances ratio analysis and the amount of responders (determined by HDRS-17 improvement and CGI outcome) compared with placebo and TCAs. All performed analysis showed a statistically significant benefit in contrast to placebo. No statistically significant differences were observed in the comparison with TCAs with regards to efficacy. When it comes to discontinuations, significantly more dropouts as a consequence of not enough efficacy were affecting the placebo treated group. No factor was seen in the comparison with TCAs. Considerably more TCA treated patients discontinued the studies than fluoxetine treated patients (while on an average of approximately Two times more); more fluoxetine treated patients discontinued for the similar reason. Overall, significantly fewer patients on fluoxetine discontinued treatment on account of any adverse event compared (compared to TCAs), while a not-significant difference in discontinuation rate for any excuse was found vs placebo. Minor variations in the Fluoxetine group, with regards to the discontinuation rate at all, just weren't discovered to be statistically significant, when compared to the placebo group. The Beasley meta-analysis is around the safety of fluoxetine in comparison with TCAs or placebo[28], substantially confirmed these leads to terms of safety. It also adds some interesting specifics of types of ADE and much better points out the role of fluoxetine's dosage. Considering only events with the incidence above 5%, that it was observed in the TCA higher group, an incidence of cholinergic ADEs (xerostomia, constipation, abnormal vision), sedation (somnolence), dizziness and peresthesia, when compared to patients using fluoxetine at dosages from 20 to 80 mg/die. Fluoxetine treated patients showed an increased incidence of nausea, insomnia, diarrhea, anorexia and rhinitis. Precisely the same style of effects were substantially seen in the comparison with placebo, but a majority of of those (nervousness, tremor, dizziness, dyspepsia) wasn't discovered to be statistically above in placebo treated patients, when only 20 mg/die dose was used. The final results in the analysis of discontinuations was consistent with the one reported from the Bech study[31]. Furthermore, the give up ratio because of adverse events of patients using 20 mg/die of fluoxetine, looked like the ratio witnessed in the placebo-treated group. These results, when it comes to safety, are substantially confirmed by the Beasley study[29] where just a 20 mg/die dosage was compared to placebo. Furthermore, these fluoxetine treated patients demonstrated significantly greater remission and response rates, mean changes on HAMD-17 total score, anxiety/somatization, retardation and cognitive disturbance factor score, than placebo treated patients (p < 0,01). Every one of these results confirm the hypothesis that fluoxetine at 20 mg/die, by far the most regularly used effective dose inside the treating depressive disorder, has an improved safety and tolerability profile weighed against higher doses of fluoxetine. The final results on the Tollefson[34] study assess that this odds of achieving a clinical response, thought as HAMD-21 score reduction from baseline for at least 50%, was similar for fluoxetine and placebo at the conclusion of week 1. However, by week 2 and after, it is likely that response was greater for fluoxetine than placebo. These results challenged the present belief a 3 to 4 week delay from the start antidepressant action isn't surprising. Bulimia
A recent Cochrane group overview around the utilization of antidepressants inside the management of bulimia nervosa, including randomized placebo-controlled studies published until 2000, found out that the application of drugs decreased the relative likelihood of binge episodes. The one SSRI as part of the analysis was fluoxetine (60 mg/die). No statistically significant differential effect may be demonstrated regarding efficacy among TCAs, SSRIs, MAOIs and other classes of antidepressants. The results of this meta-analysis reveal that patients cured with antidepressants were very likely to prematurely interrupt the treatment caused by an adverse event. Patients treated with TCAs dropped out at all more patients cured with placebo. The exact opposite was found with fluoxetine. The authors conclude, "fluoxetine is considered the most systematically studied antidepressant agent. Even when it's not superior to other drugs in terms of efficacy, its better tolerability may justify its use as a first line antidepressant in bulimia nervosa. A daily dose of 60 mg works better that the antidepressant doses of 20 mg. Two months looks like it's a suitable period to get a relevant clinical improvement. But only if a partial solution is noted, an alternative solution therapeutic approach is indicated"[27]. OCD
Inside an research into the results from one fluoxetine and a couple clomipramine studies, Jenije et al. found both treatments to function with fluoxetine having fewer negative effects. With this study seventy one treatments (clomipramine, fluoxetine and behavior therapy) were significantly effective for OCD symptoms, anxiety and depression. Only behavior therapy had not been significantly effective for depressed mood. The authors conclude: "There are nevertheless insufficient appropriate treatment studies offered to determine statistically the superiority from a treatment"[26]. Elderly depression
Around 4% on the elderly experience depressive disorder and since many as 44% experience depressive symptoms[27-31]. A minimum of three published, population-based studies associate depression inside the elderly patient with more than expected mortality[32-34]. The mean improvement in baseline-to-endpoint HAMD-17 scores was significantly greater in fluoxetine (-7. 9 ± 7. 5) vs placebo-treated patients (-6. 3 ± 7. 1) (p < 0. 01). Inside the global population the anxious and nonanxious subgroups, the analysis of psychomotor agitation, psychotic anxiety or somatic anxiety, shows a frequent, however, not statistically significant, trend in the improvement rate in fluoxetine treated patients as opposed to placebo group. The one adverse event most regularly reported by fluoxetine treated patients wisthin the anxious subgroup was nervousness (p=0. 03). No statistically significant differences were reported between fluoxetine and placebo-treated patients inside nonanxious subgroup. The proportion of fluoxetine treated patients that discontinued studies caused by a detrimental event (11. 5%) hasn't been statistically totally different from placebo treated patients (9. 6%) (p=0. 39)[33]. Suicide
Suicidal ideation, assessed while using item 3 of HAMD scale which systematically rates suicidality, was evaluated using data as of scientific tests comparing fluoxetine with TCAs and placebo. These were viewed as emergencies (any consist of 0 or One to three or 4 from the item in the double blind period) so that as "worsening" any increase from baseline. The pooled incidence of suicidal acts was 0. 3% for fluoxetine, 0. 2% for placebo and 0. 4% for TCAs; fluoxetine wouldn't differ statistically from any comparator group. Suicidal ideation emerged slightly below the significance rate, less often compared to placebo (0. 9% vs 2. 6%: p=0. 094) and numerically less often than TCAs (1. 7% vs 3. 4%; p=0. 102). The pooled incidence of substantial suicidal ideation emergencies was 1. 2% for fluoxetine, 2. 6% for placebo and three. 6% for TCAs; the incidence was significantly lower with fluoxetine compared to placebo (p=0. 042) and TCAs (p=0. 001). The pooled incidence of "worsening", since the pooled incidence of improvement of suicidal ideation, didn't differ between groups except together with the incidence of improvement with fluoxetine (72. 2%); which was statistically superior as compared to placebo (54. 8%; p < 0. 001) [30]. Pregnancy
All meta-analyses previously reviewed didn't include or failed to measure the safety of fluoxetine in expectant women. An ad-hoc meta-analysis on data of different sources, examined the increased risk for major malformations following your utilization of fluoxetine over the first trimester of pregnancy. The pooled relative risk and 95% confidence interval for major malformations does not suggest an association involving the by using fluoxetine throughout the first trimester of pregnancy plus the increased chance major malformations. The authors conclude the by using fluoxetine through the first trimester of childbearing is not connected with measurable teratogenic effects in humans[26].

• Other Sections
  • Abstract
  • Background
  • Objectives
  • Methods
  • Results
  • Discussion
  • Conclusion
  • Conflict of interests
  • References

Discussion
Fluoxetine is a widely and well-known drug proven to work for treating several diseases. Its combination of efficacy and its safety profile explains its key role within the good reputation for the pharmacotherapy of numerous diseases. Fluoxetine might be considered the conventional comparator to add mass to new drugs to be utilized inside therapy for serious and socially invasive pathologies as Major Depression, Bulimia Nervosa, Ocd, Premenstrual Dysphoric Disorder, as it confirms its effectiveness in elderly, children, adolescents and pregnant women suffering from depression. All of the above studies on depressed patients are likely to underestimate the efficacy pattern of fluoxetine, since on the style of studies considered. In fact the drop-out rate is always higher from the placebo arm compared to the fluoxetine one, making sure that those patients that has a placebo response completed the analysis and increased the revealed effectiveness of placebo. A level higher rise in the response rate or perhaps the efficacy score in the fluoxetine arm really needs to be put into the highest quantity of patients that, consistently between different studies, completed the free trial. The dose showing the higher effectiveness was 20 mg/die. Fluoxetine results also safe and efficient for your treatment of Bulimia Nervosa and OCD. Furthermore, the application of fluoxetine shows an overall improvement within the suicidal actions and ideations in depressed patients. One of the most commonly reported side effects of fluoxetine include impotence, headache and nausea, but fortunately, even the little minority of patients who've them, such effects generally disappear after about 2 weeks, although, as with other antidepressants, sexual dysfunction can persist[35]. The incidence of spontaneous adverse events resulted quite impressive, though the great majority of depressed patients were proud to report their symptoms to physician inside a controlled study environment. After we compare the real incidence of adverse events, only dry mouth appeared in over 50% of TCAs treated patients; as depressive patients usually have hypochondriacal attitudes, once they know they're in the medical trial, their strategies to specific doubts about their physical conditions overestimate their feelings compared with non-trial environment. A confirmation relating to this has become the indisputable fact that physical symptoms were often reported because of the placebo treated patients, sometimes statistically more often than inside fluoxetine arm (upper back pain arthralgia)[29].

• Other Sections
  • Abstract
  • Background
  • Objectives
  • Methods
  • Results
  • Discussion
  • Conclusion
  • Conflict of interests
  • References

Conclusion
All data through the above meta-analyses ensure that inside the management of patients with depressive disorder, fluoxetine is evenly effective as, and has now a distinctly more benign side-effect profile reducing rates of discontinuation as opposed to TCAs, is safer in overdose and easier and much easier for patients to work with and physicians to prescribe. Fluoxetine was discovered to be similar in side-effect profile to the other SSRIs, including paroxetine, sertraline, fluvoxamine and citalopram. Fluoxetine has revealed the lowest amount of dependence on dose titration of the available antidepressant. Many of the studies comparing SSRIs were Six to eight weeks in duration, only one study comparing fluoxetine and sertraline followed up 57 patients for 8 months determined the efficacy was maintained using a low incidence of adverse events[8]. In summary, fluoxetine is beneficial for all numbers of depression and it is clearly better tolerated (ie, includes a more benign adverse-events profile) and safer in the event of overdose versus the older antidepressant drugs[8]. Respond to pharmacotherapy is likely incremental, as well as the rate of response highly individualized, so more in depth focus on patient heterogeneity and early response patterns must be studied in the continuing development of any new strategy for depressive pathologies. Conflict of interests
The authors are engaged at Eli Lilly Italia S. p. A. Eli Lilly Italia paid only publication fees.

• Other Sections
  • Abstract
  • Background
  • Objectives
  • Methods
  • Results
  • Discussion
  • Conclusion
  • Conflict of interests
  • References

References

• Wong DT, Bymaster FP, Engleman EA. Minireview: Prozac (Fluoxetine, Lilly 110140), the 1st selective selective serotonin uptake inhibitor along with an antidepressant drug: 20 years since its first publication. Life Sci. 1995;57:411441. doi: 10. 1016/0024-3205(95)00209-O. [PubMed] [Cross Ref]
• Guze BH, Gitlin M. New antidepressants and the therapy for depression. J Fam Pract. 1994;38:4957. [PubMed]
• American Medical Association Drugs employed in mood disorders. Drug evaluation subscription. Vol. 1. Chicago Ill; 1992. Psychopharmacologic drugs; p. 32.
• Glass GV. Primary, secondary and meta-analysis of research. Educ Res. 1976;5:39.
• Cheer SM, Goa KL. Fluoxetine: An assessment its therapeutic potential within the treatment of depression regarding physical illness. Drugs. 2001;61:81110. [PubMed]
• Simpson K, Noble S. Fluoxetine: A review of its use in women's health. CNS Drugs. 2000;14:301328.
• Wilde MI, Benfield P. Fluoxetine: A pharmacoeconomic writeup on its utilization in depression. PharmacoEconomics. 1998;13:543561. [PubMed]
• Stokes PE, Holtz A. Fluoxetine tenth anniversary update: The progress continues. Clinical Therapeutics. 1997;19:11351150. doi: 10. 1016/S0149-2918(97)80066-5. [PubMed] [Cross Ref]
• Scott LV. Fluoxetine: A review of its pharmacology and clinical applications. Journal of Serotonin Research. 1997;3:173191.
• Bakker A, Van Balkom AJLM, Spinhoven P. SSRIs vs. TCAs inside therapy for panic disorder: A meta-analysis. Acta Psychiatrica Scandinavica. 2002;106:163167. doi: 10. 1034/j. 1600-0447. 2002. 02255. x. [PubMed] [Cross Ref]
• Khan A, Leventhal RM, Khan S, Brown WA. Suicide risk in patients with anxiety attacks: A meta-analysis on the FDA database. Journal of Affective Disorders. 2002;68:183190. doi: 10. 1016/S0165-0327(01)00354-8. [PubMed] [Cross Ref]
• Furukawa TA, Streiner DL, Young LT. Is antidepressant–benzodiazepine combination therapy clinically more useful A meta-analytic study. Journal of Affective Disorders. 2001;65:173177. doi: 10. 1016/S0165-0327(00)00254-8. [PubMed] [Cross Ref]
• Van der Linden GJH, Stein DJ, Van Balkom AJLM. The efficacy of the selective serotonin reuptake inhibitors for social panic disorder (social phobia): A meta-analysis of randomized controlled trials. International Clinical Psychopharmacology. 2000;15:S15S23. [PubMed]
• De Lima MS, Hotoph M, Wessely S. The efficacy of drug treatments for dysthymia: A systematic review and meta-analysis. Psychological Medicine. 1999;29:12731289. doi: 10. 1017/S0033291799001324. [PubMed] [Cross Ref]
• Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, McIntosh MJ, Hewett JE, Johnson JC. A meta-analysis of fibromyalgia treatment interventions. Annals of Behavioral Medicine. 1999;21:180191. [PubMed]
• Whittal MC, Agras WS, Gould RA. Bulimia nervosa: A meta-analysis of psychosocial and pharmacological treatments. Behavior Therapy. 1999;30:117135.
• Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability. Depression and Anxiety. 1998;7:1117. doi: 10. 1002/(SICI)1520-6394(1998)7:1+<11::AID-DA4>3. 3. CO;2-O. [PubMed] [Cross Ref]
• Michael KD, Crowley SL. How effective are treating child and adolescent depression A meta-analytic review. Clinical Psychology Review. 2002;22:247269. doi: 10. 1016/S0272-7358(01)00089-7. [PubMed] [Cross Ref]
• Greenberg RP, Bornstein RF, Zborowski MJ, Fisher S, Greenberg MD. A meta-analysis of fluoxetine outcome inside treating depression. Journal of Nervous and Mental Disease. 1994;182:547551. [PubMed]
• Burrows GD, Norman TR. Suicide, violent behaviour and fluoxetine: Meta-analysis of clinical trials implies that fluoxetine does not cause or increase suicidal behaviour or violent acts. Medical Journal of Australia. 1994;161:404405. [PubMed]
• Beasley CM, Jr, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH, Jr, Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN. Fluoxetine and suicide: a meta-analysis of controlled trials for the treatment of depression. BMJ. 1991;303:68592. [PMC free article] [PubMed]
• Falsetti AE. Fluoxetine–induced suicidal ideation: A test of the medical literature, case law, and also the legal liability of drug manufacturers. Food and Drug Law J. 2002;57:247267. [PubMed]
• Jarema M. The application of meta–analysis from the evaluation of antidepressive connection between fluoxetine. Psychiatria Polska. 1996;30:569581. [PubMed]
• Carr Roxane R, Ensom Mary HH. Fluoxetine in the therapy for premenstrual dysphoric disorder. The annals of pharmacotherapy. 2002;36:7137 buy prozac online without a prescription. [PubMed]
• Anderson IM. Meta–analytical studies on new antidepressants. British Medical Bulletin. 2001;57:161178. doi: 10. 1093/bmb/57. 1. 161. [PubMed] [Cross Ref]
• Jenike MA, Bear L, Greist JH. Clomipramine versus fluoxetine in obsessive-compulsive disorder: A retrospective comparison of unwanted side effects and efficacy. Journal of Clinical Psychopharmacology. 1990;10:122124. [PubMed]
• Myers JK, Weissman MM, Tischler GL, Holzer CE, 3rd, Leaf PJ, Orvaschel H, Anthony JC, Boyd JH, Burke JD, Jr, Kramer M, et al. Six-month prevalence of psychiatric disorders in three communities 1980 to 1982. Archives of General Psychiatry. 1984;41:95967. [PubMed]
• Borson S, Barnes RA, Kukull WA, Okimoto JT, Veith RC, Inui TS, Carter W, Raskind MA. Symptomatic depression in elderly medical outpatients. I. Prevalence, demography, and health service utilization. Journal from the American Geriatrics Society. 1986;34:3417. [PubMed]
• Blazer D, Hughes DC, George LK. The epidemiology of depression inside an elderly community population. Gerontologist. 1987;27:2817. [PubMed]
• Alexopoulos GS, Young RC, Meyers BS, Abrams RC, Shamoian CA. Late-onset depression. Psychiatric Clinics of United states. 1988;11:10115. [PubMed]
• Girling DM, Barkley C, Paykel ES, Gehlhaar E, Brayne C, Gill C, Mathewson D, Huppert FA. The prevalence of depression in the cohort of the very elderly. Journal of Affective Disorders. 1995;34:31929. doi: 10. 1016/0165-0327(95)00030-Q. [PubMed] [Cross Ref]
• Markush RE, Schwab JJ, Farris MA, et al. Mortality and community mental health. Arch Gen Psychiatry. 1977;34:13931401. [PubMed]
• Enzell K. Mortality among persons with depressive symptoms and among responders and non-responders within a health check-up. An investigation of persons born in 1905 and accompanied from age 66 to 75. Acta Psychiatrica Scandinavica. 1984;69:89102. [PubMed]
• Bruce ML, Seeman TE, Merrill SS, Blazer DG. The impact of depressive symptomatology on physical disability: MacArthur Studies of Successful Aging. American Journal of Public Health. 1994;84:17969. [PMC free article] [PubMed]
• xx x. Prozac (fluoxetine hydrocloride) Product Information. Dista Products Company, a division of the Eli Lilly industries, Inc, Carolina, Puerto Rico, a subdivision of Eli Lilly and Co, Indianapolis, Indiana. May 17, 1995.
• Addis A, Koren G. Safety of fluoxetine in the first trimester of childbearing: A meta–analytical report on epidemiological studies. Psychological Medicine. 2000;30:8994. doi: 10. 1017/S0033291799001270. [PubMed] [Cross Ref]
• Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. The Cochrane Library. 2003.
• Beasley CM, Jr, Koke SC, Nilsson ME, Gonzales JS. Adverse events and treatment discontinuations in clinical trials of fluoxetine in main despression symptoms: An updated meta-analysis. Clinical Therapeutics. 2000;22:13191330. doi: 10. 1016/S0149-2918(00)83028-3. [PubMed] [Cross Ref]
• Beasley CM, Jr, Nilsson ME, Koke SC, Gonzales JS. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of depressive disorder: A meta-analysis on the 20-mg/day dose. Journal of Clinical Psychiatry. 2000;61:722728. [PubMed]
• Beasley CM, Jr, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH, Jr, Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN. Fluoxetine and suicide: a meta–analysis of controlled trials for the treatment of depression. International Clinical Sychopharmacology. 1992;6:3557.
• Bech P, Cialdella P, Haugh MC, Birkett MA, Hours A, Boissel JP, Tollefson GD. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of depressive disorder. British Journal of Psychiatry. 2000;176:421428. doi: 10. 1192/bjp. 176. 5. 421. [PubMed] [Cross Ref]
• Cox BJ, Swinson RP, Morrison B, Lee PS. Clomipramine, fluoxetine, and behavior therapy inside the management of obsessive–compulsive disorder: A meta–analysis. Journal of Behavior Therapy and Experimental Psychiatry. 1993;24:149153. doi: 10. 1016/0005-7916(93)90043-V. [PubMed] [Cross Ref]
• Hoog S, Tepner R, Nilsson ME, Romano S, Kennedy JS. Changes in anxiety, agitation, and insomnia during management of depression for patients age 55 a few years older: Analysis from fluoxetine double-blind, placebo-controlled trials. International Journal of Geriatric Psychopharmacology. 1999;2:3339.
• Tollefson GD, Holman SL. Just how long to onset of antidepressant action: a meta-analysis of patients given fluoxetine or placebo. International Clinical Psychopharmacology. 1994;Winter 9:24550. [PubMed]

Articles from Annals of General Hospital Psychiatry are offered here thanks to
BioMed Central
PubMed articles by these authors

• 
  Rossi, A.


• 
  Barraco, A.


• 
  Donda, P.

PubMed related articles

• 
  Review Fluoxetine versus other kinds of pharmacotherapy for depression.

  
  Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, Malvini L, Barbui C. Cochrane Database Syst Rev. 2005 Oct 19; (4):CD004185. Epub 2005 Oct 19.

  
  

  [Cochrane Database Syst Rev. 2005]

  
  


• 
  Review [Value of fluoxetine in obsessive-compulsive disorder from the adult: review of the literature].

  
  Etain B, Bonnet-Perrin E. Encephale. 2001 May-Jun; 27(3):280-9.

  
  

  [Encephale. 2001]

  
  


• 
  Review Protection against suicide and attempted suicide in Denmark. Epidemiological studies of suicide and intervention studies in selected risk groups.

  
  Nordentoft M. Dan Med Bull. 2007 Nov; 54(4):306-69.

  
  

  [Dan Med Bull. 2007]

  
  


• 
  Review [Fluoxetine: an update of the easy use in major depressive disorder in adults].

  
  Gourion D, Perrin E, Quintin P. Encephale. 2004 Jul-Aug; 30(4):392-9.

  
  

  [Encephale. 2004]

  
  


• 
  The result of venlafaxine weighed against other antidepressants and placebo inside treatment of depressive disorder: a meta-analysis.

  
  Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N. Eur Arch Psychiatry Clin Neurosci. 2009 Apr; 259(3):172-85. Epub 2009 Jan 22.

  
  

  [Eur Arch Psychiatry Clin Neurosci. 2009]

  
  


• See reviews. . . See all. . .

Recent Activity
Clear
Turn Off
Activate

• 
  Fluoxetine: an appraisal on evidence based medicineFluoxetine: an appraisal on evidence based medicine
  

Your browsing activity is empty.

Activity recording is put off.

Turn recording back on

Links

• 
  PubMed
  

.